{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:00:19Z","timestamp":1761930019477,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T00:00:00Z","timestamp":1562284800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T00:00:00Z","timestamp":1562284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012640","name":"ExxonMobil Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012640","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Australian National Health and Medical Research Council","award":["1104975"],"award-info":[{"award-number":["1104975"]}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["1104975"],"award-info":[{"award-number":["1104975"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12936-019-2837-4","type":"journal-article","created":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T12:02:49Z","timestamp":1562328169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria: a WorldWide Antimalarial Resistance Network individual participant data meta-analysis"],"prefix":"10.1186","volume":"18","author":[{"name":"The WorldWide Antimalarial Resistance Network Methodology Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,5]]},"reference":[{"key":"2837_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695\u2013706.","journal-title":"Stat Med"},{"key":"2837_CR2","volume-title":"Methods for surveillance of antimalarial drug efficacy","author":"WHO","year":"2009","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009."},{"key":"2837_CR3","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.jclinepi.2006.07.002","volume":"59","author":"DA Southern","year":"2006","unstructured":"Southern DA, Faris PD, Brant R, Galbraith PD, Norris CM, Knudtson ML, et al. Kaplan\u2013Meier methods yielded misleading results in competing risk scenarios. J Clin Epidemiol. 2006;59:1110\u20134.","journal-title":"J Clin Epidemiol"},{"key":"2837_CR4","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1007\/s11999-015-4235-8","volume":"473","author":"S Lacny","year":"2015","unstructured":"Lacny S, Wilson T, Clement F, Roberts DJ, Faris PD, Ghali WA, et al. Kaplan\u2013Meier survival analysis overestimates the risk of revision arthroplasty: a meta-analysis. Clin Orthop Relat Res. 2015;473:3431\u201342.","journal-title":"Clin Orthop Relat Res"},{"issue":"6 Suppl","key":"2837_CR5","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1097\/MLR.0b013e3181d99107","volume":"48","author":"R Varadhan","year":"2010","unstructured":"Varadhan R, Weiss CO, Segal JB, Wu AW, Scharfstein D, Boyd C. Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications. Med Care. 2010;48(6 Suppl):S96\u2013105.","journal-title":"Med Care"},{"key":"2837_CR6","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jclinepi.2015.07.006","volume":"69","author":"C Van Walraven","year":"2016","unstructured":"Van Walraven C, McAlister FA. Competing risk bias was common in Kaplan\u2013Meier risk estimates published in prominent medical journals. J Clin Epidemiol. 2016;69:170\u20133.","journal-title":"J Clin Epidemiol"},{"key":"2837_CR7","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s12936-017-2074-7","volume":"16","author":"P Dahal","year":"2017","unstructured":"Dahal P, Simpson JA, Dorsey G, Gu\u00e9rin PJ, Price RN, Stepniewska K. Statistical methods to derive efficacy estimates of anti-malarials for uncomplicated Plasmodium falciparum malaria: pitfalls and challenges. Malar J. 2017;16:430.","journal-title":"Malar J"},{"key":"2837_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2307\/2530374","volume":"34","author":"RL Prentice","year":"1978","unstructured":"Prentice RL, Kalbfleisch JD, Peterson AV, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics. 1978;34:541\u201354.","journal-title":"Biometrics"},{"key":"2837_CR9","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141\u201354.","journal-title":"Ann Stat"},{"key":"2837_CR10","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/biostatistics\/kxl040","volume":"8","author":"PR Williamson","year":"2007","unstructured":"Williamson PR, Kolamunnage-Dona R, Tudur Smith C. The influence of competing-risks setting on the choice of hypothesis test for treatment effect. Biostatistics. 2007;8:689\u201394.","journal-title":"Biostatistics."},{"key":"2837_CR11","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:196\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"2837_CR12","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/cid\/ciy211","volume":"67","author":"CM Keene","year":"2018","unstructured":"Keene CM, Dondorp A, Crawley J, Ohuma EO, Mukaka M. A competing-risk approach for modeling length of stay in severe malaria patients in South-East Asia and the implications for planning of hospital services. Clin Infect Dis. 2018;67:1053\u201362.","journal-title":"Clin Infect Dis"},{"key":"2837_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4269\/ajtmh.18-0649","volume":"100","author":"GS Humphreys","year":"2018","unstructured":"Humphreys GS, Barnes KI, Tinto H. Strength in numbers: the WWARN case study of purpose-driven data sharing. Am J Trop Med Hyg. 2018;100:13\u20135.","journal-title":"Am J Trop Med Hyg"},{"key":"2837_CR14","unstructured":"WorldWide Antimalarial Resistance Network. Data management and statistical analysis plan Version 1.2. 2012. \n                    http:\/\/www.wwarn.org\/sites\/default\/files\/ClinicalDMSAP.pdf\n                    \n                  . Accessed 24 Sept 2018."},{"key":"2837_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/9781118032985","volume-title":"The statistical analysis of failure time data","author":"JD Kalbfleisch","year":"2002","unstructured":"Kalbfleisch JD, Prentice RL. Competing risks and multistate models. The statistical analysis of failure time data. 2nd ed. New York: Wiley; 2002. p. 247\u201377.","edition":"2"},{"key":"2837_CR16","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/sim.7215","volume":"36","author":"PC Austin","year":"2017","unstructured":"Austin PC, Fine JP. Accounting for competing risks in randomized controlled trials: a review and recommendations for improvement. Stat Med. 2017;36:1203\u20139.","journal-title":"Stat Med"},{"key":"2837_CR17","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1200\/JCO.2007.12.9866","volume":"26","author":"JJ Dignam","year":"2008","unstructured":"Dignam JJ, Kocherginsky MN. Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol. 2008;26:4027\u201334.","journal-title":"J Clin Oncol"},{"key":"2837_CR18","doi-asserted-by":"publisher","first-page":"e1001119","DOI":"10.1371\/journal.pmed.1001119","volume":"8","author":"The Four Artemisinin-Based Combinations (4ABC) Study Group","year":"2011","unstructured":"The Four Artemisinin-Based Combinations (4ABC) Study Group. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in african children: a randomized trial. PLoS Med. 2011;8:e1001119.","journal-title":"PLoS Med."},{"key":"2837_CR19","first-page":"357","volume-title":"Analysing survival data from clinical trials and observational studies","author":"M Ettore","year":"2004","unstructured":"Ettore M, Valsecchi MG. Competing risks. Analysing survival data from clinical trials and observational studies. Chichester: Wiley; 2004. p. 357. Accessed 3 Mar 2019."},{"key":"2837_CR20","unstructured":"R Foundation for Statistical Computing. R: a language and environment for statistical computing. 2017. \n                    https:\/\/www.r-project.org\/\n                    \n                  ."},{"key":"2837_CR21","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/S1473-3099(16)30020-2","volume":"16","author":"SB Sirima","year":"2016","unstructured":"Sirima SB, Ogutu B, Lusingu JPA, Mtoro A, Mrango Z, Ouedraogo A, et al. Comparison of artesunate\u2013mefloquine and artemether\u2013lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5\u00a0years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial. Lancet Infect Dis. 2016;16:1123\u201333.","journal-title":"Lancet Infect Dis."},{"key":"2837_CR22","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/sim.4384","volume":"31","author":"MT Koller","year":"2012","unstructured":"Koller MT, Raatz H, Steyerberg EW, Wolbers M. Competing risks and the clinical community: irrelevance or ignorance? Stat Med. 2012;31:1089\u201397.","journal-title":"Stat Med"},{"key":"2837_CR23","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","volume":"133","author":"PC Austin","year":"2016","unstructured":"Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133:601\u20139.","journal-title":"Circulation"},{"key":"2837_CR24","volume-title":"Guidelines for the treatment of malaria","author":"WHO","year":"2015","unstructured":"WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.","edition":"3"},{"key":"2837_CR25","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(07)60160-3","volume":"369","author":"A Ratcliff","year":"2007","unstructured":"Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung R, Laihad F, et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet. 2007;369:757\u201365.","journal-title":"Lancet"},{"key":"2837_CR26","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/EDE.0b013e3181a39056","volume":"20","author":"M Wolbers","year":"2009","unstructured":"Wolbers M, Koller MT, Witteman JCM, Steyerberg EW. Prognostic models with competing risks. Epidemiology. 2009;20:555\u201361.","journal-title":"Epidemiology."},{"key":"2837_CR27","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1093\/eurheartj\/ehu131","volume":"35","author":"M Wolbers","year":"2014","unstructured":"Wolbers M, Koller MT, Stel VS, Schaer B, Jager KJ, Leffondre K, et al. Competing risks analyses: objectives and approaches. Eur Heart J. 2014;35:2936\u201341.","journal-title":"Eur Heart J"},{"key":"2837_CR28","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1002\/sim.2054","volume":"24","author":"B Freidlin","year":"2005","unstructured":"Freidlin B, Korn EL. Testing treatment effects in the presence of competing risks. Stat Med. 2005;24:1703\u201312.","journal-title":"Stat Med"},{"key":"2837_CR29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1471-2288-14-72","volume":"14","author":"F Rotolo","year":"2014","unstructured":"Rotolo F, Michiels S. Testing the treatment effect on competing causes of death in oncology clinical trials. BMC Med Res Methodol. 2014;14:72.","journal-title":"BMC Med Res Methodol"},{"key":"2837_CR30","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1080\/00949650701473791","volume":"78","author":"R Bajorunaite","year":"2008","unstructured":"Bajorunaite R, Klein JP. Comparison of failure probabilities in the presence of competing risks. J Stat Comput Simul. 2008;78:951\u201366.","journal-title":"J Stat Comput Simul"},{"key":"2837_CR31","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/sim.2655","volume":"26","author":"M Pintilie","year":"2007","unstructured":"Pintilie M. Analysing and interpreting competing risk data. Stat Med. 2007;26:1360\u20137.","journal-title":"Stat Med"},{"key":"2837_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/1745-6215-12-127","volume":"12","author":"B-C Tai","year":"2011","unstructured":"Tai B-C, Wee J, Machin D. Analysis and design of randomised clinical trials involving competing risks endpoints. Trials. 2011;12:127.","journal-title":"Trials."},{"key":"2837_CR33","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.jclinepi.2012.09.017","volume":"66","author":"A Latouche","year":"2013","unstructured":"Latouche A, Allignol A, Beyersmann J, Labopin M, Fine JP. A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. J Clin Epidemiol. 2013;66:648\u201353.","journal-title":"J Clin Epidemiol"},{"key":"2837_CR34","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/aje\/kwp107","volume":"170","author":"B Lau","year":"2009","unstructured":"Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol. 2009;170:244\u201356.","journal-title":"Am J Epidemiol"},{"key":"2837_CR35","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1093\/ije\/dyr213","volume":"41","author":"PK Andersen","year":"2012","unstructured":"Andersen PK, Geskus RB, De Witte T, Putter H. Competing risks in epidemiology: possibilities and pitfalls. Int J Epidemiol. 2012;41:861\u201370.","journal-title":"Int J Epidemiol"},{"key":"2837_CR36","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1475-2875-5-122","volume":"5","author":"WJ Collins","year":"2006","unstructured":"Collins WJ, Greenhouse B, Rosenthal PJ, Dorsey G. The use of genotyping in antimalarial clinical trials: a systematic review of published studies from 1995\u20132005. Malar J. 2006;5:122.","journal-title":"Malar J"},{"key":"2837_CR37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.4269\/ajtmh.2003.68.133","volume":"68","author":"A Cattamanchi","year":"2003","unstructured":"Cattamanchi A, Kyabayinze D, Hubbard A, Rosenthal PJ, Dorsey G. Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of MSP-1, MSP-2, and GLURP. Am J Trop Med Hyg. 2003;68:133\u20139.","journal-title":"Am J Trop Med Hyg"},{"key":"2837_CR38","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1128\/AAC.00159-07","volume":"51","author":"B Greenhouse","year":"2007","unstructured":"Greenhouse B, Dokomajilar C, Hubbard A, Rosenthal PJ, Dorsey G. Impact of transmission intensity on the accuracy of genotyping to distinguish recrudescence from new infection in antimalarial clinical trials. Antimicrob Agents Chemother. 2007;51:3096\u2013103.","journal-title":"Antimicrob Agents Chemother"},{"key":"2837_CR39","doi-asserted-by":"publisher","first-page":"6096","DOI":"10.1128\/AAC.00072-15","volume":"59","author":"MM Plucinski","year":"2015","unstructured":"Plucinski MM, Morton L, Bushman M, Dimbu PR, Udhayakumar V. Robust algorithm for systematic classification of malaria late treatment failures as recrudescence or reinfection using microsatellite genotyping. Antimicrob Agents Chemother. 2015;59:6096\u2013100.","journal-title":"Antimicrob Agents Chemother"},{"key":"2837_CR40","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1128\/AAC.00686-12","volume":"57","author":"R Leang","year":"2013","unstructured":"Leang R, Barrette A, Bouth DM, Menard D, Abdur R, Duong S, et al. Efficacy of dihydroartemisinin\u2013piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Chemother. 2013;57:818\u201326.","journal-title":"Antimicrob Agents Chemother"},{"key":"2837_CR41","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1056\/NEJMc1403007","volume":"371","author":"DL Saunders","year":"2014","unstructured":"Saunders DL, Vanachayangkul P, Lon C. Dihydroartemisinin\u2013piperaquine failure in Cambodia. N Engl J Med. 2014;371:484\u20135.","journal-title":"N Engl J Med"},{"key":"2837_CR42","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3201\/eid2304.161872","volume":"23","author":"BQ Phuc","year":"2017","unstructured":"Phuc BQ, Rasmussen C, Duong TT, Dong LT, Loi MA, Tarning J, et al. Treatment failure of dihydroartemisinin\/piperaquine for Plasmodium falciparum malaria, Vietnam. Emerg Infect Dis. 2017;23:715\u20137.","journal-title":"Emerg Infect Dis"},{"key":"2837_CR43","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12874-019-0748-2","volume":"19","author":"P Dahal","year":"2019","unstructured":"Dahal P, Guerin PJ, Price RN, Simpson JA, Stepniewska K. Evaluating antimalarial efficacy in single-armed and comparative drug trials using competing risk survival analysis: a simulation study. BMC Med Res Methodol. 2019;19:107.","journal-title":"BMC Med Res Methodol"},{"key":"2837_CR44","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/S1471-4922(02)02373-5","volume":"18","author":"NJ White","year":"2002","unstructured":"White NJ. The assessment of antimalarial drug efficacy. Trends Parasitol. 2002;18:458\u201364.","journal-title":"Trends Parasitol"},{"key":"2837_CR45","doi-asserted-by":"publisher","first-page":"e2390","DOI":"10.1371\/journal.pone.0002390","volume":"3","author":"A Yeka","year":"2008","unstructured":"Yeka A, Dorsey G, Kamya MR, Talisuna A, Lugemwa M, Rwakimari JB, et al. Artemether\u2013lumefantrine versus dihydroartemisinin\u2013piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS ONE. 2008;3:e2390.","journal-title":"PLoS ONE"},{"key":"2837_CR46","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/1475-2875-12-250","volume":"12","author":"B Schramm","year":"2013","unstructured":"Schramm B, Valeh P, Baudin E, Mazinda CS, Smith R, Pinoges L, et al. Tolerability and safety of artesunate\u2013amodiaquine and artemether\u2013lumefantrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County, Liberia. Malar J. 2013;12:250.","journal-title":"Malar J"},{"key":"2837_CR47","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/1475-2875-12-254","volume":"12","author":"A Agarwal","year":"2013","unstructured":"Agarwal A, McMorrow M, Onyango P, Otieno K, Odero C, Williamson J, et al. A randomized trial of artemether\u2013lumefantrine and dihydroartemisinin\u2013piperaquine in the treatment of uncomplicated malaria among children in western Kenya. Malar J. 2013;12:254.","journal-title":"Malar J"},{"key":"2837_CR48","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0804915","volume":"359","author":"HA Karunajeewa","year":"2008","unstructured":"Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, Gomorrai PS, et al. A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med. 2008;359:2545\u201357.","journal-title":"N Engl J Med"},{"key":"2837_CR49","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1371\/journal.pctr.0010007","volume":"1","author":"H Bukirwa","year":"2006","unstructured":"Bukirwa H, Yeka A, Kamya MR, Talisuna A, Banek K, Bakyaita N, et al. Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clin Trials. 2006;1:e7.","journal-title":"PLoS Clin Trials"},{"key":"2837_CR50","unstructured":"WHO. Responding to antimalarial drug resistance. Geneva: World Health Organization; 2017. \n                    http:\/\/www.who.int\/malaria\/areas\/drug_resistance\/overview\/en\/\n                    \n                  . Accessed 5 Dec 2017."}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-019-2837-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12936-019-2837-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-019-2837-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T23:06:13Z","timestamp":1593817573000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-019-2837-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,5]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2837"],"URL":"https:\/\/doi.org\/10.1186\/s12936-019-2837-4","relation":{},"ISSN":["1475-2875"],"issn-type":[{"type":"electronic","value":"1475-2875"}],"subject":[],"published":{"date-parts":[[2019,7,5]]},"assertion":[{"value":"8 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The database(s) supporting the conclusions of this article are available from the WorldWide Antimalarial Resistance Network (WWARN) (), a controlled open access repository of antimalarial studies on reasonable request.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable. This study met the criteria for waiver of ethical review as defined by the Oxford Tropical Research Ethics Committee (OxTREC) as the research consists of secondary analysis of existing, anonymous data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The findings and conclusions in this report are those of the author(s) (Jimee Hwang, Mattaeusz Plucinski, Meghna Desai) and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The rest of the authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"225"}}